Surrozen Stock

surrozen.comHealthcareFounded: 2016Funding to Date: $83MM

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.

Register for Details

For more details on financing and valuation for Surrozen, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Surrozen.

Register Today

Team

Management Team

Craig Parker
Chief Executive Officer & Board Member
Roeland Nusse Ph.D
Co-Founder & Scientific Advisor
Reza Afkhami
Vice President, Corporate Development and Strategy
K. Christopher Garcia Ph.D
Co-Founder and Scientific Advisor
Calvin Kuo Ph.D
Co-Founder & Scientific Advisor
Trudy Vanhove Ph.D
Chief Medical Officer
Wen-Chen Yeh Ph.D
Chief Scientific Officer
Hans Clevers Ph.D
Co-Founder & Scientific Advisor
Claudia Janda Ph.D
Co-Founder
Timothy Kutzkey Ph.D
Chairman of the Board

Board Members

Craig Parker
David Goeddel Ph.D
The Column Group
Alexander Kamb Ph.D
Harold Varmus MD
Anna Berkenblit
Timothy Kutzkey Ph.D

Other companies like Surrozen in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

Biopharma company Surrozen secured $50m in Series B financing from Horizons Ventures, Hartford HealthCare Endowment, NS Investment and Column Group